Cargando…
Pharmacologic inhibition of Hsp90 to prevent GLT-1 degradation as an effective therapy for epilepsy
The glutamate transporter GLT-1 is critical for the maintenance of low interstitial glutamate concentrations. Loss of GLT-1 is commonly observed in neurological disorders, including temporal lobe epilepsy (TLE). Despite the hypothesis that targeting the mechanisms of GLT-1 deficiency may be a novel...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Rockefeller University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5294855/ https://www.ncbi.nlm.nih.gov/pubmed/28028152 http://dx.doi.org/10.1084/jem.20160667 |
_version_ | 1782505319582138368 |
---|---|
author | Sha, Longze Wang, Xueqin Li, Jing Shi, Xinze Wu, Liwen Shen, Yan Xu, Qi |
author_facet | Sha, Longze Wang, Xueqin Li, Jing Shi, Xinze Wu, Liwen Shen, Yan Xu, Qi |
author_sort | Sha, Longze |
collection | PubMed |
description | The glutamate transporter GLT-1 is critical for the maintenance of low interstitial glutamate concentrations. Loss of GLT-1 is commonly observed in neurological disorders, including temporal lobe epilepsy (TLE). Despite the hypothesis that targeting the mechanisms of GLT-1 deficiency may be a novel strategy for treating drug-resistant epilepsy, the underlying molecular cascade remains largely unknown. Here, we show that Hsp90β is up-regulated in reactive astrocytes of the epileptic hippocampus in patients with TLE and mouse models of epilepsy. Inhibition of Hsp90, but not Hsp70, increased GLT-1 levels. Mechanistically, Hsp90β recruits GLT-1 to the 20S proteasome, thereby promoting GLT-1 degradation. Hsp90 inhibitor prevents GLT-1 degradation by disrupting the association between Hsp90β and GLT-1. Using a model of TLE, we demonstrated that long-term systemic administration of 17AAG dramatically suppressed spontaneous recurrent seizures and ameliorated astrogliosis. Overall, these results suggest that up-regulation of GLT-1 by inhibiting Hsp90β in reactive astrocytes may be a potential therapeutic target for the treatment of epilepsy and excitotoxicity. |
format | Online Article Text |
id | pubmed-5294855 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | The Rockefeller University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-52948552017-08-01 Pharmacologic inhibition of Hsp90 to prevent GLT-1 degradation as an effective therapy for epilepsy Sha, Longze Wang, Xueqin Li, Jing Shi, Xinze Wu, Liwen Shen, Yan Xu, Qi J Exp Med Research Articles The glutamate transporter GLT-1 is critical for the maintenance of low interstitial glutamate concentrations. Loss of GLT-1 is commonly observed in neurological disorders, including temporal lobe epilepsy (TLE). Despite the hypothesis that targeting the mechanisms of GLT-1 deficiency may be a novel strategy for treating drug-resistant epilepsy, the underlying molecular cascade remains largely unknown. Here, we show that Hsp90β is up-regulated in reactive astrocytes of the epileptic hippocampus in patients with TLE and mouse models of epilepsy. Inhibition of Hsp90, but not Hsp70, increased GLT-1 levels. Mechanistically, Hsp90β recruits GLT-1 to the 20S proteasome, thereby promoting GLT-1 degradation. Hsp90 inhibitor prevents GLT-1 degradation by disrupting the association between Hsp90β and GLT-1. Using a model of TLE, we demonstrated that long-term systemic administration of 17AAG dramatically suppressed spontaneous recurrent seizures and ameliorated astrogliosis. Overall, these results suggest that up-regulation of GLT-1 by inhibiting Hsp90β in reactive astrocytes may be a potential therapeutic target for the treatment of epilepsy and excitotoxicity. The Rockefeller University Press 2017-02 /pmc/articles/PMC5294855/ /pubmed/28028152 http://dx.doi.org/10.1084/jem.20160667 Text en © 2017 Sha et al. https://creativecommons.org/licenses/by-nc-sa/4.0/http://www.rupress.org/terms/This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/). |
spellingShingle | Research Articles Sha, Longze Wang, Xueqin Li, Jing Shi, Xinze Wu, Liwen Shen, Yan Xu, Qi Pharmacologic inhibition of Hsp90 to prevent GLT-1 degradation as an effective therapy for epilepsy |
title | Pharmacologic inhibition of Hsp90 to prevent GLT-1 degradation as an effective therapy for epilepsy |
title_full | Pharmacologic inhibition of Hsp90 to prevent GLT-1 degradation as an effective therapy for epilepsy |
title_fullStr | Pharmacologic inhibition of Hsp90 to prevent GLT-1 degradation as an effective therapy for epilepsy |
title_full_unstemmed | Pharmacologic inhibition of Hsp90 to prevent GLT-1 degradation as an effective therapy for epilepsy |
title_short | Pharmacologic inhibition of Hsp90 to prevent GLT-1 degradation as an effective therapy for epilepsy |
title_sort | pharmacologic inhibition of hsp90 to prevent glt-1 degradation as an effective therapy for epilepsy |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5294855/ https://www.ncbi.nlm.nih.gov/pubmed/28028152 http://dx.doi.org/10.1084/jem.20160667 |
work_keys_str_mv | AT shalongze pharmacologicinhibitionofhsp90topreventglt1degradationasaneffectivetherapyforepilepsy AT wangxueqin pharmacologicinhibitionofhsp90topreventglt1degradationasaneffectivetherapyforepilepsy AT lijing pharmacologicinhibitionofhsp90topreventglt1degradationasaneffectivetherapyforepilepsy AT shixinze pharmacologicinhibitionofhsp90topreventglt1degradationasaneffectivetherapyforepilepsy AT wuliwen pharmacologicinhibitionofhsp90topreventglt1degradationasaneffectivetherapyforepilepsy AT shenyan pharmacologicinhibitionofhsp90topreventglt1degradationasaneffectivetherapyforepilepsy AT xuqi pharmacologicinhibitionofhsp90topreventglt1degradationasaneffectivetherapyforepilepsy |